Loading...
•
Mar 31, 2020
Amicus Therapeutics Q1 2020 Earnings Report
Amicus Therapeutics reported strong Galafold adoption and is on track to achieve 2020 revenue guidance.
Key Takeaways
Amicus Therapeutics announced its Q1 2020 financial results, highlighting the progress in advancing its mission for patients. The company is on track to achieve its 2020 key strategic priorities, including the global Fabry launch and Pompe late-stage development program. The cash runway now extends well into the second half of 2022.
Galafold 1Q2020 Revenue of $60.5 Million Reflects Continued Strong Adoption in All Key Global Regions
On track to achieve 2020 Revenue Guidance of $250M-$260M
AT-GAA in Late-Onset Pompe Disease Granted Rolling BLA Submission by U.S. FDA
Cash Runway Now Well into 2H2022
Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics Revenue by Segment
Revenue by Segment
Galafold Revenue
CapyFin.com Forward Guidance
Amicus Therapeutics is on track to achieve its 2020 key strategic priorities including its global Fabry launch, Pompe late-stage development program, and advancing its industry-leading gene therapy pipeline. The company has taken steps to prioritize spend and now sees its cash runway lasting well into the second half of 2022.
Positive Outlook
- On track to achieve 2020 key strategic priorities
- Advancing global Fabry launch
- Progressing Pompe late-stage development program
- Advancing industry-leading gene therapy pipeline
- Cash runway lasting well into the second half of 2022
Challenges Ahead
- Potential impact on operations from the COVID-19 pandemic
- Risk of clinical or preclinical studies indicating product candidates are unsafe or ineffective
- Potential difficulties in enrolling patients in clinical trials
- Risk of regulatory authorities delaying or denying approval for product candidates
- Potential inability to manufacture or supply sufficient clinical or commercial products